Abstract
Gefitinib is a tyrosine kinase inhibitor, indicated in advanced non-small cell lung cancer in all lines of treatment for patients harboring EGFR mutations. It has a favorable toxicity profile but may induce unexpected adverse effects, such as an infiammatory reaction in the bladder. We report a rare case of hemorrhagic cystitis, an unusual side effect, in a patient with non-small cell lung cancer treated with gefitinib, which did not compromise the clinical response.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / diagnosis
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / metabolism
-
Cystitis / chemically induced*
-
ErbB Receptors / drug effects*
-
ErbB Receptors / metabolism
-
Fluorodeoxyglucose F18
-
Gefitinib
-
Hemorrhage / chemically induced*
-
Humans
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / metabolism
-
Male
-
Middle Aged
-
Positron-Emission Tomography / methods
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects
-
Quinazolines / therapeutic use*
-
Remission Induction
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Quinazolines
-
Fluorodeoxyglucose F18
-
ErbB Receptors
-
Protein-Tyrosine Kinases
-
Gefitinib